| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The primary target of Sonepiprazole mesylate is the dopamine D4 receptor, a G protein-coupled receptor that is highly expressed in the prefrontal cortex, hippocampus, and limbic system. It acts as a selective antagonist with Ki values of 3.6 nM for rat D4 and 10.1 nM for human D4.2 receptors. The compound shows high selectivity for D4 over D2 (Ki = 5147 nM) and D3 (Ki = 7430 nM) receptors. By blocking D4 receptors, Sonepiprazole mesylate modulates dopaminergic signaling in brain regions involved in cognition, emotion, and reward.
|
|---|---|
| ln Vitro |
In vitro, Sonepiprazole mesylate is a selective D4 dopamine receptor antagonist with Ki values of 3.6 nM for rD4-Dopamine and 10.1 nM for hD4.2-Dopamine. It shows >1,000-fold selectivity for D4 over D2 and D3 receptors. The compound is used in radioligand binding assays to characterize D4 receptor pharmacology and in functional assays of dopamine-mediated signaling. It is a valuable tool for studying the role of D4 receptors in psychiatric disorders and cognitive function.
|
| ln Vivo |
In vivo, Sonepiprazole mesylate has been evaluated in animal models of schizophrenia and other psychiatric disorders. As a selective D4 antagonist, it may modulate dopaminergic neurotransmission in brain regions implicated in psychosis. Preclinical studies assess its effects on behaviors including locomotor activity, prepulse inhibition, and cognitive performance. Specific published in vivo efficacy data, including dosing regimens and behavioral outcomes, are reported in preclinical literature.
|
| Enzyme Assay |
The dopamine D4 receptor binding assay uses membranes from cells expressing recombinant D4 receptors. Radiolabeled dopamine or a selective D4 antagonist (e.g., [3H]spiperone) is incubated with membranes and Sonepiprazole mesylate at serial dilutions. Bound radioactivity is separated by filtration and quantified by scintillation counting. Ki values are calculated from competition curves. Selectivity is assessed against D2, D3, and other dopamine receptor subtypes.
|
| Cell Assay |
For cell-based assays, cells expressing D4 receptors are treated with Sonepiprazole mesylate. Receptor activation is assessed by measuring inhibition of forskolin-stimulated cAMP accumulation or by G-protein-coupled inwardly rectifying potassium (GIRK) channel currents using patch-clamp electrophysiology. Dopamine-induced calcium mobilization is measured using fluorescent indicators. Cell viability is evaluated using standard reagents.
|
| Animal Protocol |
In vivo studies with Sonepiprazole mesylate employ rodent models of psychiatric disorders. The compound is dissolved in saline or vehicle and administered intraperitoneally or orally. Doses are selected based on pharmacokinetic studies. Key readouts include locomotor activity, prepulse inhibition of startle response, and cognitive performance in maze tasks. Brain tissue is collected for receptor occupancy studies and neurochemical analysis.
|
| References |
| Molecular Formula |
C22H31N3O6S2
|
|---|---|
| Molecular Weight |
497.63
|
| Exact Mass |
497.165
|
| CAS # |
170858-34-1
|
| Related CAS # |
170857-36-0 (HCl);170858-33-0 170858-34-1 (mesylate);
|
| PubChem CID |
133078
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
613.9ºC at 760 mmHg
|
| Flash Point |
325.1ºC
|
| Vapour Pressure |
5.27E-15mmHg at 25°C
|
| LogP |
4.528
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
33
|
| Complexity |
685
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CS(=O)(=O)O.C1COC(C2=CC=CC=C21)CCN3CCN(CC3)C4=CC=C(C=C4)S(=O)(=O)N
|
| InChi Key |
GFNAQGUENCOUHQ-BOXHHOBZSA-N
|
| InChi Code |
InChI=1S/C21H27N3O3S.CH4O3S/c22-28(25,26)19-7-5-18(6-8-19)24-14-12-23(13-15-24)11-9-21-20-4-2-1-3-17(20)10-16-27-21;1-5(2,3)4/h1-8,21H,9-16H2,(H2,22,25,26);1H3,(H,2,3,4)/t21-;/m0./s1
|
| Chemical Name |
4-[4-[2-[(1S)-3,4-dihydro-1H-isochromen-1-yl]ethyl]piperazin-1-yl]benzenesulfonamide;methanesulfonic acid
|
| Synonyms |
PNU-101387G; Sonepiprazole mesylate; 170858-34-1; Sonepiprazole mesilate; PNU-101387G; 980MD32QLW; PNU 101387G; Sonepiprazole mesylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0095 mL | 10.0476 mL | 20.0953 mL | |
| 5 mM | 0.4019 mL | 2.0095 mL | 4.0191 mL | |
| 10 mM | 0.2010 mL | 1.0048 mL | 2.0095 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
